J Breast Cancer.  2018 Mar;21(1):87-90. 10.4048/jbc.2018.21.1.87.

Identification of the Thioredoxin-Like 2 Autoantibody as a Specific Biomarker for Triple-Negative Breast Cancer

  • 1Genomic Instability Research Center, Ajou University School of Medicine, Suwon, Korea. hckang@ajou.ac.kr
  • 2Department of Physiology, Ajou University School of Medicine, Suwon, Korea.
  • 3Department of Biomedical Sciences, Ajou University School of Medicine, Suwon, Korea.
  • 4Department of Surgery, Ajou University School of Medicine, Suwon, Korea.
  • 5Department of Bio-Engineering, Life Science RD Center, Sinil Pharmaceutical Co., Seongnam, Korea.


Triple-negative breast cancer (TNBC) has a higher risk of death within 5 years of being diagnosed than the other forms of breast cancer. It is the second leading cause of death due to cancer among women. Currently, however, no diagnostic blood-based biomarker exists to identify the early stages of TNBC. To address this point, we utilized a human protein microarray system to identify serum autoantibodies that showed different expression patterns between TNBC and normal serum samples, and identified five autoantibodies showing TNBC-specific expression. Among them, we selected the thioredoxin-like 2 (TXNL2) autoantibody and evaluated its diagnostic relevance by dot blot analysis with the recombinant TXNL2 protein. We demonstrated that the TXNL2 autoantibody showed 2- to 6-fold higher expression in TNBC samples than in normal samples suggesting that serum TXNL2 autoantibodies are potential biomarkers for TNBC.


Autoantibodies; Biomarkers; Breast neoplasms; Protein array analysis
Full Text Links
  • JBC
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr